

OPEN

Vitamin D/VDR signaling induces miR-27a/b expression in oral lichen planus

Xuejun Ge¹, Lu Yuan¹, Jizhen Wei¹, Tivoli Nguyen², Chenwei Tang², Wang Liao³, Ran Li⁴, Fang Yang¹, Fang Zhang⁴, Bin Zhao^{4,5} & Jie Du^{4*}

MicroRNA-27a/b are small non-coding RNAs which are reported to regulate inflammatory response and cell proliferation. Although some studies have demonstrated that miR-27b is down-regulated in the oral specimens of patients suffering with oral lichen planus (OLP), the molecular mechanism of miR-27b decrease remains a large mystery, and the expression of miR-27a in OLP is not well explored. Here, we demonstrated both miR-27a and miR-27b, compared with healthy controls, were reduced in the oral biopsies, serum and saliva samples derived from OLP patients. The reductions of miR-27a/b were also confirmed in the lipopolysaccharide (LPS)- or activated CD4⁺ T cell-treated human oral keratinocytes (HOKs). Furthermore, we found vitamin D receptor (VDR) binding sites in the promoters of *miR-27a/b* genes and verified this finding. We also tested miR-27a/b levels in the oral epithelium from paricalcitol-treated, vitamin D deficient or VDR knockout mice. In the rescue experiments, we confirmed vitamin D and VDR inhibited LPS- or activated CD4⁺ T cell-induced miR-27a/b reductions in HOKs. In sum, our results show that vitamin D/VDR signaling induces miR-27a/b in oral lichen planus.

Oral lichen planus, regarded as a kind of chronic mucocutaneous inflammatory disorder, is considered to be one of the potentially malignant diseases in a common consensus¹. It affects approximately 2% of the adult population with a higher prevalence in women². Although tremendous investigations have been carried out and much progress has been achieved, the pathogenesis of OLP remains a mystery. It is evident that autoimmune response, infection and mental pressure all contribute to OLP initiation and development^{3,4}. In clinic, patients suffering with OLP often show symptoms such as pain, irritation and burning, even in the process of food intake³. Histopathologic features of OLP include a typical T cell-infiltrated band in lamina propria; hyperparakeratosis, cytoid bodies and hydropic change in epithelial layer³. So far, OLP seems to be an incurable disease and most of clinical work focuses on inflammation control and symptoms reduction³. Therefore, it is urgent to investigate the pathogenesis of OLP and look for a curative way for it.

MicroRNAs (miRNAs) are a group of small, noncoding RNAs, which suppress target mRNAs expression through interacting with 3'UTR of them⁵. In published studies, miRNAs are reported to exert their biological functions in inflammation, metabolism, and development^{6–11}. In the field of OLP, several studies have regarded miRNAs as biomarkers for disease progression and malignant transformation^{12,13}. Cellular miRNA-27 is expressed throughout a variety of tissues and cell types ubiquitously and is highly conserved^{14,15}. To date, investigations of miR-27's functions are mostly focused on the immune system and cell proliferation^{10,11,14–17}. In the context of OLP, miR-27b is reported to be down-regulated in oral biopsies of OLP patients by a couple of studies^{2,18}. However, the expression of miR-27a in OLP is not clear, and the mechanism of miR-27a/b reductions is not well explained. Given this, exploitation of miR-27a/b in OLP will help us to better understand the cause of OLP.

Vitamin D, a pleiotropic hormone, plays critical roles in a broad range of biologic activities¹⁹. The active form of vitamin D, synthesized in the kidney, is referred as 1,25-dihydroxyvitamin D [1,25(OH)₂D₃]²⁰. 1,25(OH)₂D₃ takes its regulatory actions via interacting with vitamin D receptor (VDR)²¹. Vitamin D/VDR signaling is confirmed to possess regulatory functions in inflammatory diseases²². We have reported vitamin D/VDR signaling

¹Department of Periodontics, Shanxi Medical University School and Hospital of Stomatology, Taiyuan, Shanxi, China. ²Division of Biological Sciences, Department of Medicine, The University of Chicago, Chicago, Illinois, USA.

³Department of Cardiology, Hainan General Hospital, Hainan Clinical Medicine Research Institution, Haikou, China.

⁴Department of Oral Medicine, Shanxi Medical University School and Hospital of Stomatology, Taiyuan, Shanxi, China. ⁵Department of prosthodontics, Shanxi Medical University School and Hospital of Stomatology, Taiyuan, Shanxi, China. *email: dj1243@hotmail.com

is suppressed in the oral biopsies or serum samples derived from OLP patients^{23,24}. In addition, previous studies have also demonstrated that this signaling suppresses miR-802 and hypoxia-inducible factor-1 α (HIF-1 α) to ameliorate apoptosis and inflammatory reaction in HOKs^{25,26}, indicating its protective roles in OLP. In this study, we confirmed that miR-27a/b are down-regulated in oral biopsies, serum and saliva samples of OLP patients, and vitamin D/VDR signaling can induce miR-27a/b expression in OLP.

Methods and Materials

Human samples. Buccal mucosal biopsies, blood and saliva samples were collected from healthy individuals and OLP patients at the Hospital of Stomatology affiliated with Shanxi Medical University. Participants who underwent retained wisdom teeth extraction without any visible buccal inflammation were classified as healthy controls. OLP identification and inclusion criteria were set up based on the modified World Health Organization (WHO) diagnostic criteria^{27,28}. All participants involved in this study signed the written informed consent. This investigation was approved by the Ethical Committee of Shanxi Medical University. All methods were performed in accordance with the relevant guidelines and regulations. More information on OLP patients was provided in previous studies²³.

Animal studies. 8-week-old C57BL/6 mice with wildtype background were chosen experimentally for this study. Wildtype mice were administrated with vitamin D analog paricalcitol (300 ng/kg) daily for one week by intraperitoneal injection. For vitamin D deficiency model establishment, mice were placed in a dark room immediately following weaning and fed with a vitamin D deficient or normal diet for eight weeks as described before²⁹. VDR^{-/-} mice were generated in term of the previous method³⁰. Oral epithelial cells from mice were collected to isolate proteins and miRNAs. All protocols of animal studies were approved by the Ethical Committee of Shanxi Medical University. All methods were performed in accordance with the relevant guidelines and regulations.

Cell culture. Human oral keratinocytes (HOKs) were placed in 6-well plate and cultured with oral keratinocyte medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). Two types of cell models were employed to mimic OLP *in vitro*. For the first, HOKs were challenged by LPS (100 ng/ml). For the second, the supernatants from T cells culture, which were stimulated with anti-CD3/28, were added into the HOKs culture medium at a 30% final volumetric concentration²⁵. For time course-dependent experiments, HOKs were stimulated by LPS or activated CD4⁺ T cells for 0, 4, 8, 12, 24 hours, respectively. For the rest of cell models, unless otherwise specified, HOKs were challenged for 24 hours. In another experiment, HOKs were transfected with VDR or control plasmids (4 μ g) for 36 hours or pretreated with 1,25(OH)₂D₃ (20 nM) for 12 hours before LPS or activated CD4⁺ T cells treatments. VDR or empty plasmids were transfected by Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA). T cell isolation and stimulation were carried out as described before²⁵.

Oral mucosal epithelium isolation. Oral buccal tissues from human and mice were digested with 0.25% dispase II in cold room for 12 hours. Separation of epithelium and lamina propria was completed using muscle forceps as reported³¹.

Western blot. Western blot analyses were used as mentioned previously³². In brief, cells or tissues were dissolved with laemmli buffer, followed by 5-min incubation at 95 °C. Whole cell lysates were separated by SDS-PAGE gel and then transferred onto PVDF membranes. The first antibodies were used to incubate membranes overnight in cold room, followed by one-hour secondary antibody treatment at room temperature. The bands were visualized using an ECL kit (Thermo Fisher Scientific). VDR (sc-13133) and β -actin (sc-47778) antibodies were both from Santa Cruz Biotechnology (Dallas, TX, USA).

Real-time PCR. Total RNAs from HOKs or oral buccal epithelium were extracted by TRIzol Reagent (Invitrogen, Carlsbad, CA) and mRNAs were purified. The first strand cDNAs were synthesized with PrimeScript RT Reagent Kit (TaKaRa, Mountain View, CA) and real-time PCRs were performed with a SYBR Premix Ex Kit (TaKaRa). miRNAs from tissues and cells were isolated with miRNA isolation kit (Life Technologies), and the circulating miRNAs from serum and saliva were obtained with mirVana PARIS kit (Life Technologies) according to the manufacturer's instructions. cDNA synthesis and real-time PCR were completed using either a specific miRNA First-strand cDNA Synthesis Kit (Aidlab Biotechnologies, Beijing, China) or an miRNA Real-time PCR Assay Kit (Aidlab Biotechnologies) accordingly. Relative amounts of transcripts were analyzed by the $2^{-\Delta\Delta Ct}$ formula. For circulating miRNA samples, the same amount of exogenous cel-miR-39 was added before miRNA extraction and served as normalization. Sequences of PCR primers were shown in Table 1.

Chromatin immunoprecipitation (ChIP) assays. ChIP assays were carried out using a commercial kit according to the manufacture instruction. In brief, HOK cells transfected with VDR or empty plasmids were fixed in 1% formaldehyde and then treated with glycine for neutralization. Cell lysates were sonicated and precipitated with the help of antibody (VDR or IgG) and protein A agarose. After elution and a series of washes, samples were quantified by qPCR. The primers for ChIP assay were provided in Table 1.

Statistical analysis. Data are shown as means \pm SD. 2 groups data were analyzed using 2-tailed Student's *t* test, and multiple groups data were analyzed by one-way ANOVA. *P* < 0.05 was considered statistically significant.

| Primer name | Forward(5'-3') | Reverse(5'-3') |
|--------------------|--------------------------|--------------------------|
| Hsa-mir-27a | TTCACAGTGGCTAAGTTCCGC | |
| Hsa-mir-27b | TTCACAGTGGCTAAGTTCTGC | |
| Has-miR-16 | TAGCAGCACGTAATATTGGCG | |
| Mmu-mir-27a | TTCACAGTGGCTAAGTTCCGC | |
| Mmu-mir-27b | TTCACAGTGGCTAAGTTCTGC | |
| U6 | GATGACACGCAAATTCGTGAA | |
| miR-27a ChIP site1 | GATGGAGAGGAGATCGTGC | GAGCCAGTGACACAAACCAAC |
| miR-27a ChIP site2 | GCCTGGCCCTTTATTGTTT | GGTGGTGGGTGCCTGTAA |
| miR-27a ChIP site3 | CCCAGTTCACAGATTCTCC | CATGGCGAAACTCGGTCT |
| miR-27b ChIP | TGCCACAAGAAGGCTATTATCCA | CTGCTCTCATATCAGCACTTCC |
| hsa-let-7a-2 ChIP | CCTGCCTTGTGTCCATTTCATAAG | GTCTTCTGCTACTAGATGCTCACT |
| hVDR | GACTTTGACCGGAACGTGCCC | CATCATGCCGATGTCCACACA |
| hTNF α | CCTCTCTTAATCAGCCCTCTG | GAGGACCTGGGAGTAGATGAG |
| hIL-6 | TGAGGAGACTTGCCCTGGTGA | GTTGGGTGAGGGGTGGTTAT |
| hIFN γ | TGAACATGATGGATCGTTGG | CATTCACTTTGCTGGCAGTG |
| hSNAP25 | ACCAGTTGGCTGATGAGTCG | CAAAGTCTGATACCAGCATCTT |
| hTXN2 | CTGGTGGCCTGACTGTAACAC | TGACCACCTGGTCTTGAAGT |
| hGADPH | ACCACAGTCCATGCCATCAC | TCCACCACCCTGTTGCTGTA |

Table 1. Primer sequences involved in this work.

Results

miR-27a/b are down-regulated in OLP patients and OLP models. Previous studies have demonstrated that miR-27b shows a significant decrease in oral biopsies of OLP patients^{2,12,18}. To confirm the miR-27b expression and exploit miR-27a in OLP, we collected oral epithelium, blood and saliva samples from individuals to investigate miR-27a/b levels. As shown in Fig. 1, miR-27a/b were decreased in the epithelial layer of oral biopsies (Fig. 1a,b) of OLP patients. Furthermore, circulating miR-27a/b levels of serum were lower in OLP group than those in health controls (Fig. 1c,d), and so were they in saliva samples (Fig. 1e,f). As autoimmune response and infection are both able to induce OLP, to better mimic it *in vitro*, we treated HOKs with LPS or activated CD4⁺ T cell supernatants to establish OLP models. As expected, miR-27a/b were down-regulated in the two cell models in a time-dependent manner (Fig. 2a–d). TNF α , IL-6 and IFN γ , selected as positive controls, were also enhanced in the presence of LPS or activated CD4⁺ T cell supernatants (Supplemental Fig. 1a–f). Importantly, LPS or activated CD4⁺ T cell supernatants had no effects on miR-16 which is used for a negative control (Supplemental Fig. 2a,b).

VDR binds to its elements in the promoters of miR-27a/b to enhance their expression in HOKs. To determine the mechanism of miR-27a/b decreases in OLP, we examined the promoters of miR-27a/b, where we found VDR elements (VDREs) (Fig. 3a). It seems there are three putative VDR binding sites (1–3) in the promoter of miR-27a (Supplemental Fig. 3a), but our ChIP data showed that only VDRE-2 and VDRE-3 comprise the authentic binding sites for VDR (Fig. 3b and Supplemental Fig. 3c). Furthermore, compared with the mild increase in HOKs transfected with empty plasmids, VDR overexpression largely enhanced the combination of VDR and VDRE (Supplemental Fig. 3d,e). What is more, there is a VDRE in the promoter of miR-27b (Supplemental Fig. 3b), which was confirmed by ChIP assay in HOKs transfected with or without VDR plasmids (Fig. 3c and Supplemental Fig. 3f). To further verify the role of VDR in miR-27a/b induction, we transfected VDR plasmids into HOKs and tested miR-27a/b inductions. As shown in Fig. 3, miR-27a/b levels were highly increased in the presence of VDR plasmids (Fig. 3d). Hsa-let-7a-2, a positive control for VDRE investigation³³, also displayed higher expression in HOKs after VDR overexpression (Supplemental Fig. 3g). SNAP25 and TXN2 are two target genes of miR-27a/b¹⁴, and we next sought to explore the expression of them. Accompanied with miR-27a/b increases, VDR overexpression down-regulated SNAP25 and TXN2 levels (Supplemental Fig. 3h). Vitamin D is reported to activate VDR in most kinds of cells to exert its biological functions²¹. To this end, we added 1,25(OH)₂D₃ into HOKs culture medium in this investigation. As displayed, vitamin D mildly up-regulated miR-27a/b status (Fig. 3e). Pharmacological inhibition of bromodomain-containing protein 9 (iBRD9) is reported to enhance VDR's biological function³⁴, and our data showed that iBRD9 facilitated vitamin D to increase miR-27a/b expression (Fig. 3e).

Vitamin D/VDR signaling regulates miR-27a/b expression in oral epithelial cells of mice. To further detect the effect of vitamin D/VDR signaling on miR-27a/b *in vivo*, we treated C57BL/6 mice with paricalcitol. Accompanied with increase of VDR expression, miR-27a/b levels were up-regulated in the oral epithelial cells (Fig. 4a,b). In contrast, expression of miR-27a/b of oral epithelium was down-regulated in vitamin D deficient or VDR knockout mice, which showed either VDR decrease or VDR deletion (Fig. 4c–f). These results provide evidence for the mediation of vitamin D/VDR signaling on miR-27a/b *in vivo*.

Inhibition of vitamin D/VDR signaling results in miR-27a/b decreases in OLP. Our previous studies have indicated that status of VDR in biopsies and vitamin D in serum are down-regulated in OLP patients^{23,24},




Figure 1. miR-27a/b levels are down-regulated in OLP patients. (a,b) The levels of miR-27a (a) and miR-27b (b) in human oral epithelia measured by qPCR. (c,d) The expression of miR-27a (c) and miR-27b (d) in human serum monitored by qPCR. (e,f) miR-27a (e) and miR-27b (f) status in human saliva detected by real-time PCR. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs. corresponding healthy controls; $n = 14$.

which indicates the cause of miR-27a/b decreases in OLP might be, at least in part, due to vitamin D/VDR signaling suppression. In accordant with the results regarding human samples, we tested VDR expression in the two kinds of cell models and found their levels were compromised in HOKs with LPS or activated CD4⁺ T cell treatment (Fig. 5a–d). Accordingly, positive correlations were observed between VDR and miR-27a/b in oral epithelial cells obtained from OLP patients and controls (Fig. 6a,b [$r = 0.7681$, $P = 0.0236$, Spearman's correlation test for miR-27a] and [$r = 0.7282$, $P = 0.0417$, Spearman's correlation test for miR-27b]), and 25(OH)D and miR-27a/b in serum from participants also showed good correlations (Fig. 6c,d [$r = 0.6605$, $P = 2.78 \times 10^{-11}$, Spearman's correlation test for miR-27a] and [$r = 0.7305$, $P = 2.80 \times 10^{-11}$, Spearman's correlation test for miR-27b]).

If suppression of vitamin D/VDR signaling leads to miR-27a/b decreases in OLP, we hypothesized that vitamin D or VDR treatment would be likely to rescue them. To investigate this hypothesis, we pretreated HOKs with vitamin D or VDR plasmids before LPS or activated CD4⁺ T cell challenge. As shown, VDR plasmids transfection reversed miR-27a/b decreases in the presence of activated CD4⁺ T cell or LPS in HOKs (Fig. 7a,b), and so did 1,25(OH)₂D₃ pretreatment (Fig. 7c,d). Moreover, VDR overexpression also ameliorated miR-27a/b decreases in cell culture medium (Supplemental Fig. 4a,b). Accordantly, vitamin D/VDR signaling attenuated TNF α productions in HOKs with LPS or activated CD4⁺ T cell treatment (Supplemental Fig. 4c–f). Together, these data manifest that vitamin D/VDR signaling blockage is one of the reasons of miR-27a/b reductions in OLP.




Figure 2. miR-27a/b levels are reduced in LPS- or activated CD4⁺ T cell-treated HOKs. (a and b) miR-27a (a) and miR-27b (b) levels in activated CD4⁺ T cell-treated HOKs determined by qPCR at different time points as indicated. (c,d) Real-time PCR quantification of miR-27a (c) and miR-27b (d) levels in HOKs treated with time course-dependent LPS. *P < 0.05, **P < 0.01, ***P < 0.001 vs. corresponding control; n = 3.




Figure 3. Vitamin D and VDR promote miR-27a/b expression in HOKs. (a) Schematic illustration of VDR binding sites in *miR-27a/b* promoters. (b) ChIP analysis indicating the up-regulation of VDR binding sites in *miR-27a* in HOKs transfected with VDR plasmids after IgG or VDR antibodies precipitation as indicated. Sites 1–3 mean VDREs 1–3, correspondingly. Bar demonstrates log₂ fold change, n = 3 for each site. (c) ChIP analysis indicating the up-regulation of VDR binding site in *miR-27b* in HOKs transfected with VDR plasmids after IgG or VDR antibodies treatment. Bar demonstrates log₂ fold change, n = 3 for this site. (d) Real-time PCR test of miR-27a/b levels in HOKs transfected with or without VDR plasmids. (e) Real-time PCR determination of miR-27a/b in HOKs with different treatments as indicated. **P < 0.01, ***P < 0.001 vs. corresponding control; n = 3. Ctrl, control; 1,25VD, 1,25(OH)₂D₃.




Figure 4. miR-27a/b expression is mediated by vitamin D and VDR *in vivo*. (a,b) VDR expression (a) and miR-27a/b levels (b) of oral epithelial cells were measured by western blot and qPCR respectively in paricalcitol-treated mice. (c,d) Western blot and qPCR showing VDR (c) and miR-27a/b (d) status of oral epithelium in vitamin D deficient mice. (e,f) Western blot and qPCR displaying VDR expression (e) and miR-27a/b levels (f) of oral epithelial layer in VDR knockout mice. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs. corresponding control or WT; $n = 5$. Ctrl, control; pari, paricalcitol; VDRKO, VDR knockout; VD-D, vitamin D-deficiency; WT, wildtype.

Discussion

In this study, we collected oral biopsies, serum and saliva samples from both OLP patients and healthy participants to detect miR-27a/b expression. Compared with healthy controls, miR-27a/b levels were consistently compromised in the three types of samples from OLP patients. These findings are in agreement with previous notes that miR-27b is down-regulated in oral biopsies obtained from OLP patients^{2,18}. Importantly, we further investigated miR-27a/b status in OLP cell models by employing LPS treatment to mimic infection conditions in HOKs or adopting activated CD4⁺ T cell supernatants to simulate the microenvironment of autoimmune response. Consistent with the observations found in human samples, miR-27a/b levels showed robust decreases in the two kinds of cell models, providing compelling evidence for our findings.

The major biological activities of miR-27a and miR-27b in bodies are demonstrated to be associated with immune response, cell proliferation and development. In HeLa cells, miR-27 targets SNAP25 and TXN2 to block adenovirus infection¹⁴. Earlier reports have claimed that miR-27 suppresses inflammatory responses by regulating T-cell functions and cytokines productions^{10,15}. On the contrary, miR-27 overexpression has the ability of impairing Treg differentiation¹⁷. For cell proliferation, miR-27 is demonstrated to promote osteosarcoma cell growth and accelerate chondrogenic differentiation^{16,35}, while other studies identify miR-27 as a tumor suppressor in renal cell carcinoma³⁶. These inconsistent observations create an unclear understanding regarding the function of miR-27. In the field of OLP, some investigations have suggested that miR-27b targets PLK2 to promote oral keratinocytes proliferation³⁷. Due to the inflammatory conditions, miR-27a/b's functions may be largely involved in immune response in the context of OLP. This hypothesis requires further investigations in our following project. Herein, we focused on the mechanism of miR-27a/b reductions in OLP.




Figure 5. VDR levels show significant decreases in OLP cell models. (a and b) VDR mRNA (a) or protein (b) levels in HOKs treated with or without activated CD4⁺ T cells tested by qPCR or western blot. (c,d) VDR mRNA (c) or protein (d) levels in HOKs in the presence or absence of LPS treatment detected by qPCR or western blot. * $P < 0.05$, ** $P < 0.01$ vs. corresponding control; $n = 3$. Ctrl, control.




Figure 6. Vitamin D/VDR and miR-27a/b show good positive correlations in OLP patients and healthy controls. (a,b) Correlations of VDR and miR-27a (a)/miR-27b (b) in human oral epithelial cells from OLP patients and healthy controls ($r = 0.7681$, $P = 0.0236$, Spearman's correlation test for miR-27a; $r = 0.7282$, $P = 0.0417$, Spearman's correlation test for miR-27b), $n = 14$. (c,d) Correlations of 25(OH)D and miR-27a (c)/miR-27b (d) in human serum derived from OLP patients and healthy controls ($r = 0.6605$, $P = 2.78 \times 10^{-11}$, Spearman's correlation test for miR-27a; $r = 0.7305$, $P = 2.80 \times 10^{-11}$, Spearman's correlation test for miR-27b), $n = 14$.




Figure 7. Vitamin D and VDR increase miR-27a/b in OLP cell models. (a,b) Real-time PCR showing miR-27a/b levels in HOKs treated with activated CD4⁺ T cells (a) or LPS (b) with or without VDR plasmids transfection as indicated. (c,d) Real-time PCR indicating miR-27a/b expression in HOKs treated with activated CD4⁺ T cells (c) or LPS (d) in the presence or absence of 1,25 VD. *P < 0.05, **P < 0.01, ***P < 0.001 vs. corresponding control; #P < 0.05, ##P < 0.01, ###P < 0.001 vs CD3/28 or LPS group; n = 3. Ctrl, control; 1,25VD, 1,25(OH)₂D₃.

Our recent data have indicated that vitamin D/VDR signaling plays a protective role in OLP by inhibiting cytokines secretion and apoptosis in oral keratinocytes^{25,26}. In the current study, we located VDR binding sites in the promoter regions of *miR-27a/b*, implying vitamin D/VDR signaling possesses the potential of inducing miR-27a/b expression. We then carried out ChIP assays to confirm that VDR enhances miR-27a/b transcripts via binding with VDREs. Additionally, VDR plasmids transfection, but not 1,25(OH)₂D₃ treatment, considerably improved miR-27a/b yields in HOKs, indicating the primary role of VDR in the vitamin D/VDR signaling. This observation is accordant with previous reports which note that VDR is a key modulator of β cell survival, stromal reprogramming and liver fibrosis^{34,38,39}. Since some studies have reported the biological functions of vitamin D are limited in several fields⁴⁰, we suggest more attentions should be placed on VDR itself rather than the vitamin D hormone. Does vitamin D/VDR signaling regulate miR-27a/b transcripts in mice? To answer this question, we established three kinds of models. Our data suggested that vitamin D treatment raised miR-27a/b expression in oral epithelial cells of mice, whereas vitamin D deficiency or VDR deletion decreased them. These cell line and mouse data together identify a key role of oral epithelial vitamin D/VDR signaling in the mediation of miR-27a/b expression.

We have demonstrated that VDR levels of oral epithelium are down-regulated by approximately 50% and the 25(OH)D status of serum shows a > 50% decrease in OLP patients in early explorations^{23,24}. Consistent with the human data, we further showed a ~50% VDR decrease in OLP cell models. Based on these results, we drew a conclusion that vitamin D/VDR signaling suppression contributes to miR-27a/b decreases in OLP. Importantly, good positive correlations between VDR/25(OH)D and miR-27a/b were found in oral specimens or serum from OLP patients. Due to the lack of well-established OLP animal models, we can not investigate the correlation of VDR and miR-27a/b under diseased conditions in mice.

Vitamin D or VDR overexpression has been proven to perform its regulatory functions in oral epithelium of OLP by impeding nuclear factor- κ B (NF- κ B) pathway or by inducing von Hippel-Lindau (VHL)^{25,26}. In this work, we found that either VDR plasmids transfection or vitamin D treatment attenuated LPS or activated CD4⁺ T cell supernatant-induced miR-27a/b decreases in OLP cell models, proposing a notion that vitamin D/VDR signaling may control miR-27a/b expression to exert its physiological actions in OLP and expand the regulatory networks of vitamin D/VDR signaling.

In conclusion, this work indicates vitamin D/VDR signaling accelerates miR-27a/b expression in OLP. Upon binding with VDREs, vitamin D facilitates VDR to improve miR-27a/b transcripts in oral epithelial cells. Thus, miR-27a/b reductions in OLP may be due, at least in part, to vitamin D/VDR signaling suppression. Although the mechanism of miR-27a/b reductions has been elaborated, the roles of miR-27a/b in OLP development still require further investigations to better understand the pathogenies of this disease.

Received: 5 August 2019; Accepted: 24 December 2019;

Published online: 15 January 2020

References

- van der Waal, I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. *Oral oncology* **45**, 317–323, <https://doi.org/10.1016/j.oraloncology.2008.05.016> (2009).
- Zhang, W. Y. *et al.* Altered microRNA expression profile with miR-27b down-regulation correlated with disease activity of oral lichen planus. *Oral diseases* **18**, 265–270, <https://doi.org/10.1111/j.1601-0825.2011.01869.x> (2012).

3. Cheng, Y. S., Gould, A., Kurago, Z., Fantasia, J. & Muller, S. Diagnosis of oral lichen planus: a position paper of the American Academy of Oral and Maxillofacial Pathology. *Oral surgery, oral medicine, oral pathology and oral radiology* **122**, 332–354, <https://doi.org/10.1016/j.oooo.2016.05.004> (2016).
4. Gorouhi, F., Davari, P. & Fazel, N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. *TheScientificWorldJournal* **2014**, 742826, <https://doi.org/10.1155/2014/742826> (2014).
5. Mendell, J. T. & Olson, E. N. MicroRNAs in stress signaling and human disease. *Cell* **148**, 1172–1187, <https://doi.org/10.1016/j.cell.2012.02.005> (2012).
6. Dumortier, O., Hinault, C. & Van Obberghen, E. MicroRNAs and metabolism crosstalk in energy homeostasis. *Cell metabolism* **18**, 312–324, <https://doi.org/10.1016/j.cmet.2013.06.004> (2013).
7. Vacchio, M. S. & Bosselut, R. T cell metabolism: microRNAs cap PTEN to feed the expanding crowd. *Immunity* **38**, 847–848, <https://doi.org/10.1016/j.immuni.2013.05.006> (2013).
8. Tao, G. & Martin, J. F. MicroRNAs get to the heart of development. *eLife* **2**, e01710, <https://doi.org/10.7554/eLife.01710> (2013).
9. Schuld, A. MicroRNAs diversify in drosophila development. *Nature cell biology* **7**, 781, <https://doi.org/10.1038/ncb0805-781> (2005).
10. Pua, H. H. *et al.* MicroRNAs 24 and 27 suppress allergic inflammation and target a network of regulators of T helper 2 cell-associated cytokine production. *Immunity* **44**, 821–832, <https://doi.org/10.1016/j.immuni.2016.01.003> (2016).
11. Suarez, Y., Wang, C., Manes, T. D. & Pober, J. S. Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. *Journal of immunology* **184**, 21–25, <https://doi.org/10.4049/jimmunol.0902369> (2010).
12. Aghbari, S. M. H., Gaafar, S. M., Shaker, O. G., El Ashiry, S. & Zayed, S. O. Evaluating the accuracy of microRNA27b and microRNA137 as biomarkers of activity and potential malignant transformation in oral lichen planus patients. *Archives of Dermatological Research* **310**, 209–220, <https://doi.org/10.1007/s00403-018-1805-0> (2018).
13. Ahmadi-Motamayel, F. *et al.* Evaluation of the miRNA-146a and miRNA-155 expression levels in patients with oral lichen planus. *Iran J Immunol* **14**, 316–324 (2017).
14. Machitani, M. *et al.* MicroRNA miR-27 inhibits adenovirus infection by suppressing the expression of SNAP25 and TXN2. *Journal of virology* **91**, <https://doi.org/10.1128/JVI.00159-17> (2017).
15. Guo, Y. E., Riley, K. J., Iwasaki, A. & Steitz, J. A. Alternative capture of noncoding RNAs or protein-coding genes by herpesviruses to alter host T cell function. *Molecular Cell* **54**, 67–79, <https://doi.org/10.1016/j.molcel.2014.03.025> (2014).
16. Ye, P. *et al.* Up-regulated MiR-27-3p promotes the G1-S phase transition by targeting inhibitor of growth family member 5 in osteosarcoma. *Biomed Pharmacother* **101**, 219–227, <https://doi.org/10.1016/j.biopha.2018.02.066> (2018).
17. Cruz, L. O. *et al.* Excessive expression of miR-27 impairs Treg-mediated immunological tolerance. *The Journal of clinical investigation* **127**, 530–542, <https://doi.org/10.1172/JCI88415> (2017).
18. Aghbari, S. M., Zayed, S. O., Shaker, O. G. & Abushouk, A. I. Evaluating the role of tissue microRNA-27b as a diagnostic marker for oral lichen planus and possible correlation with CD8. *Journal of oral pathology & medicine* **48**, 68–73, <https://doi.org/10.1111/jop.12785> (2019).
19. Bouillon, R. *et al.* Vitamin D and human health: lessons from vitamin D receptor null mice. *Endocrine reviews* **29**, 726–776, <https://doi.org/10.1210/er.2008-0004> (2008).
20. Lim, W. C., Hanauer, S. B. & Li, Y. C. Mechanisms of disease: vitamin D and inflammatory bowel disease. *Nature clinical practice. Gastroenterology & hepatology* **2**, 308–315, <https://doi.org/10.1038/ncpgasthep0215> (2005).
21. Haussler, M. R. *et al.* The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. *Journal of bone and mineral research* **13**, 325–349, <https://doi.org/10.1359/jbmr.1998.13.3.325> (1998).
22. Liu, W. *et al.* Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. *The Journal of clinical investigation* **123**, 3983–3996, <https://doi.org/10.1172/JCI65842> (2013).
23. Jie, D. *et al.* Experimental study on 1,25(OH)₂D₃ amelioration of oral lichen planus through regulating NF-κB signaling pathway. *Oral diseases* **23**, 770–778, <https://doi.org/10.1111/odi.12659> (2017).
24. Zhao, B. *et al.* LPS-induced vitamin D receptor decrease in oral keratinocytes is associated with oral lichen planus. *Scientific reports* **8**, 763, <https://doi.org/10.1038/s41598-018-19234-z> (2018).
25. Zhao, B. *et al.* Vitamin D/VDR signaling suppresses microRNA-802-induced apoptosis of keratinocytes in oral lichen planus. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* **33**, 1042–1050, <https://doi.org/10.1096/fj.201801020RRR> (2018).
26. Ge, X. *et al.* Vitamin D/VDR signaling inhibits LPS-induced IFNγ and IL-1β in oral epithelia by regulating hypoxia-inducible factor-1α signaling pathway. *Cell communication and signaling* **17**, 18, <https://doi.org/10.1186/s12964-019-0331-9> (2019).
27. van der Meij, E. H. & van der Waal, I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. *Journal of oral pathology & medicine* **32**, 507–512 (2003).
28. Cheng, Y. S. *et al.* Salivary endothelin-1 potential for detecting oral cancer in patients with oral lichen planus or oral cancer in remission. *Oral oncology* **47**, 1122–1126, <https://doi.org/10.1016/j.oraloncology.2011.07.032> (2011).
29. Du, J., Wei, X., Ge, X., Chen, Y. Y. & Li, Y. C. Microbiota-dependent induction of colonic Cyp27b1 is associated with colonic inflammation: implications of locally produced 1,25-Dihydroxyvitamin D3 in inflammatory regulation in the colon. *Endocrinology* **158**, 4064–4075, <https://doi.org/10.1210/en.2017-00578> (2017).
30. Li, Y. C. *et al.* Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. *Proceedings of the National Academy of Sciences of the United States of America* **94**, 9831–9835 (1997).
31. Wang, Y. *et al.* Total glucosides of paeony (TGP) inhibits the production of inflammatory cytokines in oral lichen planus by suppressing the NF-κB signaling pathway. *International immunopharmacology* **36**, 67–72, <https://doi.org/10.1016/j.intimp.2016.04.010> (2016).
32. Du, J. *et al.* 1,25-Dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway. *Inflammatory bowel diseases* **21**, 2495–2506, <https://doi.org/10.1097/MIB.0000000000000526> (2015).
33. Guan, H. *et al.* 1,25-Dihydroxyvitamin D₃ up-regulates expression of hsa-let-7a-2 through the interaction of VDR/VDRE in human lung cancer A549 cells. *Gene* **522**, 142–146, <https://doi.org/10.1016/j.gene.2013.03.065> (2013).
34. Wei, Z. *et al.* Vitamin D switches BAF complexes to protect beta cells. *Cell* **173**, 1135–1149, <https://doi.org/10.1016/j.cell.2018.04.013> (2018).
35. Kara, N., Wei, C., Commanday, A. C. & Patton, J. G. miR-27 regulates chondrogenesis by suppressing focal adhesion kinase during pharyngeal arch development. *Developmental biology* **429**, 321–334, <https://doi.org/10.1016/j.ydbio.2017.06.013> (2017).
36. Li, Y. Y. *et al.* MicroRNA-27a functions as a tumor suppressor in renal cell carcinoma by targeting epidermal growth factor receptor. *Oncology Letters* **11**, 4217–4223, <https://doi.org/10.3892/ol.2016.4500> (2016).
37. Chen, J. *et al.* Downregulated miR-27b promotes keratinocyte proliferation by targeting PLK2 in oral lichen planus. *Journal of oral pathology & medicine* **48**, 326–334, <https://doi.org/10.1111/jop.12826> (2019).
38. Ding, N. *et al.* A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. *Cell* **153**, 601–613, <https://doi.org/10.1016/j.cell.2013.03.028> (2013).
39. Sherman, M. H. *et al.* Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. *Cell* **159**, 80–93, <https://doi.org/10.1016/j.cell.2014.08.007> (2014).

40. Zhao, J. G., Zeng, X. T., Wang, J. & Liu, L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. *JAMA* **318**, 2466–2482, <https://doi.org/10.1001/jama.2017.19344> (2017).

Acknowledgements

This work was supported by National Natural Science Foundation of China grants (81800499) and a grant from Shanxi Medical University.

Author contributions

D.J. conceived and designed this project. G.X.J., Y.L. and W.J.Z. performed the assays. L.R., Y.F. and Z.F. collected samples. D.J., L.W. and Z.B. analyzed data. D.J. wrote the manuscript. N.T. and T.C.W. worked for proofreading. D.J. acquired funding.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-019-57288-9>.

Correspondence and requests for materials should be addressed to J.D.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020